Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Carrier used for medicine giving for intestine

A carrier and drug delivery technology, used in antipyretics, drug combinations, pharmaceutical formulations, etc., and can solve problems such as major changes in bioavailability

Active Publication Date: 2007-11-21
VITAL HEALTH SCIENCES PTY LTD
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For any drug, changing the formulation has the potential to significantly alter its bioavailability

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Carrier used for medicine giving for intestine
  • Carrier used for medicine giving for intestine
  • Carrier used for medicine giving for intestine

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0049] In this experiment, the efficacy was compared between the morphine composition of the present invention and morphine sulfate (currently used enteral formulation of morphine). The effect of the drug was measured by comparing the time it took for morphine-treated and non-morphine-treated rats to withdraw their paws after exposure to heat.

[0050] Material

[0051] Animals: Nine conscious Sprague-Dawley rats, each weighing 350-450 grams.

[0052] Treatment group:

[0053] 1. Control: water,

[0054] 2. Morphine sulfate,

[0055] 3. Morphine with TPm: Morphine hydrochloride (14%) (TPm) in a carrier containing water (59%) and tocopheryl phosphate mixture (27%). The TPm contains monotocopheryl phosphate and ditocopheryl phosphate.

[0056] Formulations 2 and 3 were diluted with water to achieve a final morphine concentration of 5 mg / ml. For example, 0.357 grams of Formulation 3 is mixed with 0.643 grams of water to give a final concentration of morphine of 5%. The liq...

example 2

[0070] This example studies the bioavailability of coenzyme Q10 (CoQ10) in guinea pigs after administration of the following formulations:

[0071] A. CoQsol

[0072] B. CoQsol and TPM in MCT

[0073] C.MCT oil (control)

[0074] Materials and methods

[0075] preparation

[0076] Tocopheryl phosphate mixture (TPM) containing 2:1 w / w mono-tocopheryl phosphate (TP) and di-tocopheryl phosphate (T2P) was manufactured by Phosphagenics.

[0077] CoQsol was purchased from American Doctor's Trust Vitamins company.

[0078] Medium-chain triglycerides (MCT) were manufactured by Abitec Corporation of the United States.

[0079] These preparations include:

[0080] A. CoQsol: Each softgel contains 60mg CoQ and 0.44ml oily content of the pill. So the concentration of CoQ in the capsule contents is 60mg / 0.44ml=136mgCoQ / ml. CoQsol formulations also contain 136IU d-alpha-tocopherol and 3705IU vitamin A per milliliter. Excipients are rice bran oil, gelatin, glycerin, water, beeswax, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

There is provided a carrier for use in enteral administration of biologically active compounds, said carrier comprising an effective amount of one or more phosphate derivatives of one or more electron transfer agents.

Description

technical field [0001] The present invention relates to carriers for enteral administration of biologically active compounds. Background technique [0002] In this description, although a scientific and technological document, a certain knowledge or a certain knowledge point is mentioned or discussed, such citation or discussion is not deemed to admit that the document, knowledge or knowledge point is part of the common knowledge on the priority date , or considered relevant to solving the problems involved in this specification. [0003] The main purpose of drug delivery is to obtain the appropriate biological effect at the site of action. If the drug formulation does not have the correct physicochemical properties to release it at the target site, the biological activity of the drug will not be optimal, so the choice of formulation is critical to drug efficacy. [0004] Drugs come in different dosage forms, usually divided into parenteral and parenteral dosage forms. En...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K47/22A61K31/355A61K31/375A61K31/07A61K31/59A61P29/00
Inventor S・M・维斯特E・区格鲁
Owner VITAL HEALTH SCIENCES PTY LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products